Patent US5906615A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4929442A Expired / Lapsed US ⏱️ 0.0 years remaining

Compositions suitable for human topical application including a growth factor and/or related materials

Assignee: Exovir Inc
•
Filing: 1986-09-26
•
Granted: 1990-05-29
•
Expires: 2006-09-26
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compositions containing a tissue plasminogen activator (t-PA), epidermal growth factor (EGF), transforming growth factor-alpha (TGF alpha ), transforming growth factor-beta (TGF- beta ), human endothelial cell growth factor (ECGF), granulocyte macrophage colony stimulating factor (GM-CSF) and a fibronectin or large external transformation sensitive protein (LETS) including cell surface protein (CSP), cell adhesion protein (CAP), cell insoluble globulin (CIG) and/or opsonic-alpha 2 surface binding glycoprotein in a suitable physiologically acceptable carrier are useful for the treatment of humans when topically and/or subcutaneously applied. These compositions might also usefully contain or have employed in association therewith an adjuvant to aid in the transdermal transport or transfer of the compositions, particularly the active components therein, through or across the skin. Also, these compositions might also have contained therein or employed in association therewith an antiviral agent, such as an antiviral surfactant, for example, an antiviral nonionic surfactant, e.g. nonylphenoxypolyethoxy ethanol and/or human interferon, e.g. alpha-interferon. Additionally, these compositions might contain or have employed in association therewith an antitumor agent, such as tumor necrosis factor (TNF), target cell lysis factor (TCLF) and carcino-breaking factor (CBF). These compositions are useful in the treatment or healing of humans, e.g. in the treatment of viral and/or cancerous skin disorders or lesions and/or to expedite healing.

Inventors

  • 👤 Maxwell M. Powell

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 16:21
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/49; A61K38/17; A61K38/19; A61K38/21; A61P; A61P17/00; A61P35/00

Claims Analysis

Total Claims: 14
Claim 1
Independent Claim 141 words
A composition suitable for topical or subcutaneous application to a human for the treatment of cancerous or virus-caused skin disorders consisting essentially of a physiologically acceptable carrier, an antiviral or anti-cancer effective amount of a biologically active material selected from the group consisting of tissue plasminogen activator (t-PA), epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), human endothelial cell growth factor (ECGF), granulocyte macrophage colony stimulating factor (GM-CSF), and a fibronectin or large external transformation sensitive protein (LETS) selected from the group of cell surface protein (CSP), cell adhesion protein (CAP), cell insoluble globulin (CIG) and opsonic-alpha 2 surface binding protein, an effective antiviral amount of an antiviral surfactant, an effective antiviral amount of human interferon and an effective amount of an adjuvant to assist in the transdermal transport or transfer of said composition through the skin.
Claim 2
Dependent Claim 141 words
A composition suitable for topical or subcutaneous application to a human for the treatment of cancerous or virus-caused skin disorders consisting essentially of a physiologically acceptable carrier, an antiviral or anti-cancer effective amount of a biologically active material selected from the group consisting of tissue plasminogen activator (t-PA), epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), human endothelial cell growth factor (ECGF), granulocyte macrophage colony stimulating factor (GM-CSF), and a fibronectin or large external transformation sensitive protein (LETS) selected from the group of cell surface protein (CSP), cell adhesion protein (CAP), cell insoluble globulin (CIG) and opsonic-alpha 2 surface binding protein, an effective antiviral amount of an antiviral surfactant, an effective antiviral amount of human interferon and an effective amount of an adjuvant to assist in the transdermal transport or transfer of said composition through the skin.
Claim 3
Dependent Claim 14 words
A composition in accordance with claim 1 wherein said human interferon is human alpha-interferon.
Claim 4
Dependent Claim 15 words
A composition in accordance with claim 1 wherein said antiviral surfactant is a nonionic surfactant.
Claim 5
Dependent Claim 14 words
A composition in accordance with claim 1 wherein said antiviral surfactant is nonylphenoxypolyethoxy ethanol.
Claim 6
Dependent Claim 12 words
A composition in accordance with claim 1 wherein said adjuvant is dimethylsulfoxide.
Claim 7
Dependent Claim 13 words
A composition in accordance with claim 1 wherein said adjuvant is a glycol.
Claim 8
Dependent Claim 30 words
A composition in accordance with claim 1 wherein said composition additionally contains an antitumor agent selected from the group consisting of a lymphotoxin, tumor necrosis factor (TNF) and an interleukin.
Claim 9
Dependent Claim 14 words
A composition in accordance with claim 1 wherein said carrier is an aqueous gel.
Claim 10
Dependent Claim 38 words
A composition in accordance with claim 1 wherein said carrier is an aqueous gel and wherein said antiviral surfactant is present in an amount in the range from about 0.1 to about 20% by weight of said composition.
Claim 11
Independent Claim 140 words
A method for treating cancerous or virus-caused skin disorders of a human which comprises topically or subcutaneously applying a composition consisting essentially of a physiologically acceptable carrier, an antiviral or anti-cancer effective amount of a biologically active material selected from the group consisting of tissue plasminogen (tPA), epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), human endothelial cell growth factor (ECGF) granulocyte macrophage colony stimulating factor (GM-CSF) and a fibronectin or large external transformation sensitive protein (LETS) selected from the group consisting of cell surface protein (CSP), cell adhesion protein (CAP), cell insoluble globulin (CIG), opsonic-alpha 2 surface binding protein, an effective antiviral amount of an antiviral surfactant, an effective antiviral amount of human interferon and an effective amount of an adjuvant to assist in the transdermal transport or transfer of said composition through the skin.
Claim 12
Independent Claim 140 words
A method for treating cancerous or virus-caused skin disorders of a human which comprises topically or subcutaneously applying a composition consisting essentially of a physiologically acceptable carrier, an antiviral or anti-cancer effective amount of a biologically active material selected from the group consisting of tissue plasminogen (tPA), epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), human endothelial cell growth factor (ECGF) granulocyte macrophage colony stimulating factor (GM-CSF) and a fibronectin or large external transformation sensitive protein (LETS) selected from the group consisting of cell surface protein (CSP), cell adhesion protein (CAP), cell insoluble globulin (CIG), opsonic-alpha 2 surface binding protein, an effective antiviral amount of an antiviral surfactant, an effective antiviral amount of human interferon and an effective amount of an adjuvant to assist in the transdermal transport or transfer of said composition through the skin.
Claim 13
Dependent Claim 31 words
A method in accordance with claim 10 wherein said applied composition additionally contains an anti-tumor agent selected from the group consisting of a lymphotoxin, tumor necrosis factor (TNF) and an interleukin.
Claim 14
Dependent Claim 73 words
A method in accordance with claim 10 wherein said physiologically acceptable carrier comprises an aqueous gel, wherein said antiviral surfactant is a nonionic surfactant, wherein said human interferon is human alpha interferon, wherein said adjuvant is selected from the group consisting of dimethylsulfoxide and a glycol and wherein said composition additionally includes an effective amount of an anti-tumor agent selected from the group consisting a lymphotoxin, tumor necrosis factor (TNF) and an interleukin.

References Cited (Backward Citations)

US3917824A Cited
US3948875A Cited
US4621052A Cited
US4373519A Cited
US4507281A Cited
US4609546A Cited
US4743679A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1993-05-28 1993-11-27 1994-05-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1997-05-28 1997-11-27 1998-05-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2001-05-28 2001-11-27 2002-05-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag